Tandem Diabetes Care, Inc. TNDM
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -15.06%
- 1 year
- +33.36%
- Open
- 19.35
- Prev close
- 19.11
- Mkt cap
- 1.30B
- Vol
- 2.72M
- Avg vol
- 2.14M
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.42
- High
- 19.45
- Forward P/E
- 117.45
- Beta
- 1.59
- Short ratio
- 6.27
- Inst. own
- 115.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 18.02
- 200-d avg
- 18.93
- 1y target
- 27.76
News
3 days ago businesswire.com
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the…
4 days ago zacks.com
Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 weeks ago defenseworld.net
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the…
3 weeks ago benzinga.com
Tandem Diabetes Care Q2 2026 Earnings Call Transcript
Tandem Diabetes Care (NASDAQ:TNDM) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…
3 weeks ago zacks.com
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
-
3 weeks ago benzinga.com
Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18
Barclays analyst Christopher Pasquale initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Equal-Weight rating and announces Price Target of $18.
1 month ago businesswire.com
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial…
-
1 month ago benzinga.com
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
1 month ago defenseworld.net
Head to Head Contrast: Solventum (NYSE:SOLV) & Tandem Diabetes Care (NASDAQ:TNDM)
Tandem Diabetes Care (NASDAQ: TNDM - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies…
1 month ago gurufocus.com
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
[url="]Tandem Diabetes Care, Inc[/url]. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world'
1 month ago businesswire.com
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
1 month ago zacks.com
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near…
1 month ago gurufocus.com
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued
On September 10, 2026, Tandem Diabetes Care Inc (TNDM) shares fell 4.2% to a current price of $18.31. The stock has experienced notable volatility, trading betw
1 month ago zacks.com
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
2 months ago benzinga.com
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
-
2 months ago benzinga.com
William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating
William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.
2 months ago benzinga.com
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in…
2 months ago benzinga.com
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
2 months ago marketbeat.com
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and…
2 months ago zacks.com
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
2 months ago benzinga.com
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading…
-
2 months ago benzinga.com
Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $17 to $21.
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26
RBC Capital analyst Kendall Au maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price target from $30 to $26.
2 months ago marketbeat.com
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its…
2 months ago seekingalpha.com
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.48 per share a year ago.
2 months ago zacks.com
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with…
-
2 months ago benzinga.com
Tandem Diabetes Care Q2 EPS $(0.31) Beats $(0.32) Estimate, Sales $254.560M Miss $254.978M Estimate
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 60.26 percent increase over losses of…
-
2 months ago benzinga.com
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.
2 months ago businesswire.com
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter…
-
3 months ago benzinga.com
Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
3 months ago zacks.com
Does TNDM Stock Still Deserve a Place in Your Portfolio?
Tandem Diabetes Care, Inc. TNDM is well-poised to grow in the coming quarters as the rising prevalence of diabetes and increasing adoption of connected care continue to support demand for automated…
4 months ago benzinga.com
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.
-
4 months ago benzinga.com
Deutsche Bank Initiates Coverage On Tandem Diabetes Care with Hold Rating, Announces Price Target of $15.5
Deutsche Bank analyst Kieran Ryan initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Hold rating and announces Price Target of $15.5.
-
5 months ago benzinga.com
Tandem Diabetes Care Receives CE Mark For Expanded Indications Of Its Automated Insulin Delivery Systems In Europe
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indications of its automated insulin delivery…
-
5 months ago benzinga.com
Wells Fargo Upgrades Tandem Diabetes Care to Overweight, Raises Price Target to $27
Wells Fargo analyst Larry Biegelsen upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Equal-Weight to Overweight and raises the price target from $21 to $27.
-
5 months ago benzinga.com
Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $17
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $22 to $17.
-
5 months ago benzinga.com
B of A Securities Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25
B of A Securities analyst Travis Steed maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $35 to $25.
5 months ago benzinga.com
This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.
-
5 months ago benzinga.com
Truist Securities Reiterates Buy on Tandem Diabetes Care, Lowers Price Target to $31
Truist Securities analyst Richard Newitter reiterates Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and lowers the price target from $35 to $31.
-
5 months ago benzinga.com
Barclays Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $55
Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight and lowers the price target from $56 to $55.
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.076B Est.
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.076 billion estimate.
-
5 months ago benzinga.com
Tandem Diabetes Care Q1 Adj. EPS $(0.30) Beats $(0.45) Estimate, Sales $247.221M Beat $241.125M Estimate.
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.45) by 33.33 percent. This is a 54.55 percent increase over losses…
6 months ago benzinga.com
FDA Flags High-Risk Recall For Tandem Diabetes Mobi Pumps
FDA flags Class I recall for Tandem Mobi insulin pumps tied to software glitch that may halt insulin delivery, with four injuries reported.
-
6 months ago benzinga.com
TD Cowen Maintains Buy on Tandem Diabetes Care, Raises Price Target to $28
TD Cowen analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $25 to $28.
-
6 months ago benzinga.com
Goldman Sachs Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25
Goldman Sachs analyst David Roman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $28 to $25.
7 months ago benzinga.com
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves
MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising competition and past share losses.
7 months ago benzinga.com
Nvidia To $323? Here Are 10 Top Analyst Forecasts For Thursday
Analyst ratings changed for top Wall Street names. Morgan Stanley cut Carnival Corp price target, Raymond James raised NVIDIA Corp's target and more.
7 months ago benzinga.com
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday
Top Wall Street analysts upgraded Carnival Corp, Tandem Diabetes Care, and Union Pacific Corp. Analysts see potential in UNP stock.